- Total product sales of €64.0 million
- In-line with expectations; full-year guidance of €135 -150 million reaffirmed
- Solid cash position of €121.5 million as of end June 2026
- Reflects disciplined cash management and proceeds from the recent reserved offering [1]
- Restructuring program implemented with positive P&L and cash flow impacts expected in the second half of the year and beyond
- Regulatory decisions for Lyme disease vaccine candidate expected in the next twelve months [2]
- Pfizer remains optimistic about obtaining registration for the vaccine candidate [3]
Lyon (France), August 13, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported its condensed consolidated financial results for the first half of the year ended June 30, 2026, provided key corporate updates, and reaffirmed its financial guidance for 2026. The half year financial report, including the condensed consolidated interim financial report and the half year management report, is available on the Company’s website (Financial Reports – Valneva).
Valneva will provide a live webcast of its half year 2026 results conference call beginning at 3 p.m. CEST / 9 a.m. EDT today. This webcast will also be available on the Company’s website. Please refer to this link: https://edge.media-server.com/mmc/p/zd7jniit/lan/en
To access the full release, please click on the PDF below.
[1] Valneva Announces the Successful Completion of an €84 million Reserved Offering – Valneva
[2] https://s206.q4cdn.com/795948973/files/doc_financials/2026/q2/Q2-2026-Earnings-Charts-FINAL.pdf
[3] https://s206.q4cdn.com/795948973/files/doc_events/2026/Jun/08/PFE-USQ_Transcript_2026-06-08.pdf